Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease
Research is underway to develop an early medical test for Alzheimer's disease (AD).
To evaluate potential demand for such a test, we conducted a cross-sectional telephone survey of 2,678 randomly selected adults across the United States and four European countries.
Most surveyed adults (67%) reported that they are "somewhat" or "very likely" to get an early medical test if one becomes available in the future. Interest was higher among those worried about developing AD, those with an immediate blood relative with AD, and those who have served as caregivers for AD patients. Older respondents and those living in Spain and Poland also exhibited greater interest in testing. Knowing AD is a fatal condition did not influence demand for testing, except among those with an immediate blood relative with the disease.
Potential demand for early medical testing for AD could be high. A predictive test could not only advance medical research, it could transform political and legal landscapes by creating a large constituency of asymptomatic, diagnosed adults.
- DeKosky ST, Carrillo MC, Phelps C, Knopman D, Petersen RC, Frank R, Schenk D, Masterman D, Siemers ER, Cedarbaum JM: Revision of the criteria for Alzheimer's disease: a symposium. Alzheimers Dement 2011, 7:e1-e12. CrossRef
- Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH: Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement 2011, 7:280–292. CrossRef
- Ballard C, Corbett A, Jones EL: Dementia: challenges and promising developments. Lancet Neurol 2011, 10:7–9. CrossRef
- Johnstone D, Milward EA, Berretta R, Moscato P, Alzheimer's Disease Neuroimaging Initiative: Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset. PLoS ONE 2012, 7:e34341. CrossRef
- Rosenstock I: Why people use health services. Milbank Mem Fund Q 2005, 83:1–32.
- Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E: Alzheimer's disease. Lancet 2011, 377:1019–1031. CrossRef
- Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA 1997, 278:1349–1356. CrossRef
- Goldman JS, Hahn SE, Catania JW, Larusse-Eckert S, Butson MB, Rumbaugh M, Strecker MN, Roberts JS, Burke W, Mayeux R, Bird T: Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med 2011, 13:597–605. CrossRef
- Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, et al.: Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes. Nat Genet 2009, 41:1088–1093. CrossRef
- Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, Bis JC, Smith AV, Carassquillo MM, Lambert JC, Harold D, Schrijvers EM, Ramirez-Lorca R, Debette S, Longstreth WT Jr, Janssens AC, Pankratz VS, Dartigues JF, Hollingworth P, Aspelund T, Hernandez I, Beiser A, Kuller LH, Koudstaal PJ, Dickson DW, Tzourio C, Abraham R, Antunez C, Du Y, Rotter JI, et al.: Genome-wide analysis of genetic loci associated with Alzheimer's disease. JAMA 2010, 303:1832–1840. CrossRef
- Mattsson N, Blennow K, Zetterberg H: CSF biomarkers: pinpointing Alzheimer pathogenesis. Ann N Y Acad Sci 2009, 1180:28–35. CrossRef
- Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative: Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009, 65:403–413. CrossRef
- Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K: Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 2008, 4:38–48. CrossRef
- Hochbaum GM: Public Participation in Medical Screening Programs: a Socio-psychological Study. Washington, D.C.: Public Health Service, U.S. Government Printing Office; 1958. PHS 972
- Janz NK, Becker MH: The Health Belief Model: a decade later. Health Educ Q 1984, 11:1–47. CrossRef
- Gooding HC, Linnenbringer EL, Burack J, Roberts JS, Green RC, Biesecker BB: Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk. Patient Educ Couns 2006, 64:259–267. CrossRef
- Roberts JS: Anticipating response to predictive genetic testing for Alzheimer's disease: a survey of first-degree relatives. Gerontologist 2000, 40:43–52. CrossRef
- Green R, Clarke V, Thompson N, Woodard J, Letz R: Early detection of Alzheimer disease: methods, markers, and misgivings. Alzheimer Dis Assoc Disord 1997,11(Suppl 5):S1–5. discussion S37–39
- Becker MH, Kaback MM, Rosenstock IM, Ruth MV: Some influences on public participation in a genetic screening program. J Community Health 1975, 1:3–14. CrossRef
- Champion VL, Skinner CS: The Health Belief Model. In Health Behavior and Health Education: Theory, Research, and Practice. 4th edition. Edited by: Glanz K, Rimer B, Viswanath K. San Francisco, CA: John Wiley & Sons; 2008:45–65.
- Quaid K, Morris M: Reluctance to undergo predictive testing: the case of Huntington disease. Am J Med Genet 1993, 45:41–45. CrossRef
- Christensen KD, Roberts JS, Uhlmann WR, Green RC: Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease risk. Genet Med 2011, 13:409–414. CrossRef
- Blendon RJ, Benson JM, Wikler EM, Weldon KJ, Georges J, Baumgart M, Kallmyer BA: The impact of experience with a family member with Alzheimer's disease on views about the disease across five countries. Int J Alzheimers Dis 2012, 2012:903645. CrossRef
- Strecher V, Rosenstock I: The Health Belief Model. In Cambridge Handbook of Psychology, Health and Medicine. 1st edition. Edited by: Baum A, Newman S, Weinman J, West R, McManus C. Cambridge, UK: Cambridge University Press; 1997:113–116.
- Neumann PJ, Hammitt JK, Mueller C, Fillit HM, Hill J, Tetteh NA, Kosik KS: Public attitudes about genetic testing for Alzheimer's disease. Health Aff (Millwood) 2001, 20:252–264. CrossRef
- Marteau TM, Croyle RT: The new genetics: psychological responses to genetic testing. BMJ 1998, 316:693–696. CrossRef
- Evers-Kiebooms G, Welkenhuysen M, Claes E, Decruyenaere M, Denayer L: The psychological complexity of predictive testing for late onset neurogenetic diseases and hereditary cancers: implications for multidisciplinary counselling and for genetic education. Soc Sci Med 2000, 51:831–841. CrossRef
- Roberts JS, Barber M, Brown TM, Cupples LA, Farrer LA, LaRusse SA, Post SG, Quaid KA, Ravdin LD, Relkin NR, Sadovnick AD, Whitehouse PJ, Woodard JL, Green RC: Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial. Genet Med 2004, 6:197–203. CrossRef
- Neumann PJ, Cohen JT, Hammitt JK, Concannon TW, Auerbach HR, Fang C, Kent D: Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Econ 2012, 21:238–251. CrossRef
- Kopits IM, Chen C, Roberts JS, Uhlmann W, Green RC: Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility. Genet Test Mol Biomarkers 2011, 15:871–875. CrossRef
- Dudokdewit AC, Tibben A, Niermeijer MF: Psychological distress in applicants for predictive DNA testing for autosomal dominant, heritable, late onset disorders. J Med Genet 1997, 34:382–390. CrossRef
- Wimo A, Jönsson L, Gustavsson A, McDaid D, Ersek K, Georges J, Gulácsi L, Karpati K, Kenigsberg P, Valtonen H: The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project. Int J Geriatr Psychiatry 2011, 26:825–832. CrossRef
- Vas CJ, Rajkumar S, Tanyakitpisal P, Chandra V: Alzheimer's Disease: The Brain Killer: When Old Age Becomes A Disease. New Delhi: WHO Regional Office for South-East Asia; 2001.
- Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, Seynaeve C, Tilanus-Linthorst MM, Wagner A, Dukel L, Devilee P, van den Ouweland AM, van Geel AN, Klijn JG: Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 2000, 355:2015–2020. CrossRef
- Connell CM, Roberts JS, McLaughlin SJ, Carpenter BD: Black and white adult family members' attitudes toward a dementia diagnosis. J Am Geriatr Soc 2009, 57:1562–1568. CrossRef
- Peters N, Rose A, Armstrong K: The association between race and attitudes about predictive genetic testing. Cancer Epidemiol Biomarkers Prev 2004, 13:361–365.
- Halbert CH, Kessler L, Stopfer JE, Domchek S, Wileyto EP: Low rates of acceptance of BRCA1 and BRCA2 test results among African American women at increased risk for hereditary breast-ovarian cancer. Genet Med 2006, 8:576–582. CrossRef
- Tambor ES, Rimer BK, Strigo TS: Genetic testing for breast cancer susceptibility: awareness and interest among women in the general population. Am J Med Genet 1997, 68:43–49. CrossRef
- Singer E, Antonucci T, Van Hoewyk J: Racial and ethnic variations in knowledge and attitudes about genetic testing. Genet Test 2004, 8:31–43. CrossRef
- Akinleye I, Roberts JS, Royal CD, Linnenbringer E, Obisesan TO, Fasaye GA, Green RC: Differences between African American and White research volunteers in their attitudes, beliefs and knowledge regarding genetic testing for Alzheimer's disease. J Genet Couns 2011, 20:650–659. CrossRef
- Connell C, Roberts JS: Public opinion about Alzheimer disease among blacks, hispanics, and whites: results from a national survey. Alzheimer Dis Assoc Disord 2007, 21:232–240. CrossRef
- Hall M, Olopade OI: Confronting genetic testing disparities. JAMA 2005, 293:1783–1785. CrossRef
- Jonassaint CR, Santos ER, Glover CM, Payne PW, Fasaye GA, Oji-Njideka N, Hooker S, Hernandez W, Foster MW, Kittles RA, Royal CD: Regional differences in awareness and attitudes regarding genetic testing for disease risk and ancestry. Hum Genet 2010, 128:249–260. CrossRef
- Deyo RA: Cascade effects of medical technology. Annu Rev Public Health 2002, 23:23–44. CrossRef
- Farran C, James B, Johnson T, Scholz K, Weuve J: 2011 Alzheimer's disease facts and figures. Alzheimers Dement 2011, 5:1–66.
- Neumann PJ, Cohen JT, Hammitt JK, Concannon TW, Auerbach HR, Fang C, Kent DM: Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Econ 2012, 21:238–251. CrossRef
- Post SG, Whitehouse PJ, Binstock RH, Bird TD, Eckert SK, Farrer LA, Fleck LM, Gaines AD, Juengst ET, Karlinsky H, Miles S, Murray TH, Quaid KA, Relkin NR, Roses AD, St George-Hyslop PH, Sachs GA, Steinbock B, Truschke EF, Zinn AB: The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. JAMA 1997, 277:832–836. CrossRef
- Roberts JS, Uhlmann WR: Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues. Prog Neurobiol 2013, in press.
- Zick CD, Mathews CJ, Roberts JS, Cook-Deegan R, Pokorski RJ, Green RC: Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior. Health Aff (Millwood) 2005, 24:483–490. CrossRef
- Oster E, Shoulson I, Quaid K, Dorsey ER: Genetic adverse selection: evidence from long-term care insurance and Huntington disease. J Public Econ 2010, 94:1041–1050. CrossRef
- Van Hoyweghen I, Horstman K: European practices of genetic information and insurance: lessons for the Genetic Information Nondiscrimination Act. JAMA 2008, 300:326–327. CrossRef
- Oster E, Dorsey ER, Bausch J, Shinaman A, Kayson E, Oakes D, Shoulson I, Quaid K, Huntington Study Group PHAROS Investigators: Fear of health insurance loss among individuals at risk for Huntington disease. Am J Med Genet A 2008, (146A):2070–2077.
- Tambor ES, Bernhardt BA, Chase GA, Faden RR, Geller G, Hofman KJ, Holtzman NA: Offering cystic fibrosis carrier screening to an HMO population: factors associated with utilization. Am J Hum Genet 1994, 55:626–637.
- Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, Gold K, Trock B, Main D, Lynch J, Fulmore C, Snyder C, Lemon SJ, Conway T, Tonin P, Lenoir G, Lynch H: BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA 1996, 275:1885–1892. CrossRef
- Miller SM: Monitoring and blunting: validation of a questionnaire to assess styles of information seeking under threat. J Pers Soc Psychol 1987, 52:345–353. CrossRef
- Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Alzheimer's Research & Therapy
- Online Date
- September 2013
- Online ISSN
- BioMed Central
- Additional Links
- Alzheimer's disease
- medical testing
- predictive testing
- medical decision-making
- public attitudes
- Author Affiliations
- 1. Harvard Graduate School of Arts and Sciences, 14 Story Street, 4th Floor, Cambridge, MA, 02138, USA
- 2. Department of Health Policy and Management, 677 Huntington Avenue, Kresge Building, Room 402, Boston, MA, 02115, USA